Literature DB >> 14997309

[New therapeutic approaches in the treatment of shock: hypertonic hyperoncotic solutions and vasopressin].

A Meier-Hellman1, G Burgard.   

Abstract

The extreme disturbance of hemodynamics in shock leads to a minimized oxygen delivery to several vital organs. If this state is not rapidly lifted, a multi-organ-failure can occur. In addition to the removal of the underlying causes, for example, bleeding or septic focus, measures must be started to stabilize hemodynamics. In most cases shock can be successfully treated with standard therapeutic interventions including the use of crystalloid or colloid solutions as well as the infusion of inotropes or vasopressors. Up to now, there is not enough evidence to show that hypertonic/hyperoncotic solutions are better for treating hypovolemic shock than standard infusions, other than in situations, where only an inadequate equipment is available. Experimental data support the use of vasopressin instead of fluid loading in case of uncontrolled intra-abdominal bleeding. According to these studies vasopressin seems to be associated with an improved hemodynamic stabilization and a significantly lower mortality rate. However, no clinical tests have been done so far to confirm these results. In septic shock the plasma-levels of vasopressin are low. It has been shown that the infusion of vasopressin contributes to stabilization of hemodynamics in septic shock, in lower, as well as in higher concentrations. On the other hand vasopressin worsens splanchnic perfusion. Therefore the routine use of vasopressin in the treatment of sepsis can not be recommended.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997309     DOI: 10.1007/s00108-003-1141-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  58 in total

1.  Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers.

Authors:  G Nilsson; P Lindblom; M Ohlin; R Berling; E Vernersson
Journal:  Drugs Exp Clin Res       Date:  1990

2.  Survival after hypertonic saline resuscitation from hemorrhage.

Authors:  M H Soliman; H Ragab; K Waxman
Journal:  Am Surg       Date:  1990-12       Impact factor: 0.688

3.  Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.

Authors:  I Tsuneyoshi; H Yamada; Y Kakihana; M Nakamura; Y Nakano; W A Boyle
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

4.  Vasopressin deficiency contributes to the vasodilation of septic shock.

Authors:  D W Landry; H R Levin; E M Gallant; R C Ashton; S Seo; D D'Alessandro; M C Oz; J A Oliver
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

5.  A comparison of isotonic and hypertonic solutions and blood on blood flow and oxygen consumption in the initial treatment of hemorrhagic shock.

Authors:  A E Baue; E T Tragus; W M Parkins
Journal:  J Trauma       Date:  1967-09

6.  Hypertonic saline dextran resuscitation during the initial phase of acute endotoxemia: effect on regional blood flow.

Authors:  U Kreimeier; L Frey; J Dentz; T Herbel; K Messmer
Journal:  Crit Care Med       Date:  1991-06       Impact factor: 7.598

7.  Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial.

Authors:  K L Mattox; P A Maningas; E E Moore; J R Mateer; J A Marx; C Aprahamian; J M Burch; P E Pepe
Journal:  Ann Surg       Date:  1991-05       Impact factor: 12.969

8.  Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries.

Authors:  W H Bickell; M J Wall; P E Pepe; R R Martin; V F Ginger; M K Allen; K L Mattox
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

9.  Hypertonic sodium chloride solutions: effect on hemodynamics and survival after hemorrhage in swine.

Authors:  L W Traverso; R F Bellamy; S J Hollenbach; L D Witcher
Journal:  J Trauma       Date:  1987-01

Review 10.  Controversies in shock research: hypertonic resuscitation--pros and cons.

Authors:  M M Krausz
Journal:  Shock       Date:  1995-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.